Characteristics and factors influencing viral decay under tenofovir (TDF) and adefovir (ADV) need to be determined in HIV–HBV-coinfected patients.
Methods
This open-label study compared the HBV dynamics in 85 HIV–HBV-coinfected patients initiating an antiretroviral regimen, either including TDF or associated with ADV. The first 6-month change in viral load was analysed using mixed linear models. The adjusted hazards ratio, comparing the rates of undetectable HBV DNA between treatments, was calculated using a Cox proportional hazard model.
Results
The HBV DNA decay, adjusted for baseline HBV viral load was more pronounced in patients treated with TDF than with ADV at 12 months (66% versus 53%, P=0.0001). Patients in the TDF group presented a steeper slope of decline at 1.1 (95% confidence interval [CI] 0.9–1.3), compared with 0.8 (95% CI 0.6–1.0) in the ADV group (P=0.036). The mean time to HBV DNA undetectability was 19.3 months (95% CI 16.7–22.0) with TDF and 25.9 months (95% CI 21.1–30.7) with ADV. When adjusted for hepatitis B virus e antigen, HBV DNA and alanine aminotransferase levels at baseline, the influence of treatment on time to HBV DNA undetectability remained in favour of TDF versus ADV (hazard ratio=2.79, 95% CI 1.05–7.40, P=0.039)
Conclusions
TDF influenced more strongly the early-phase HBV DNA kinetics than ADV. This is associated with a sustained antiviral activity in the TDF group, in which patients reached the threshold of HBV undetectability at a faster rate and in a larger proportion than those taking ADV.
References
1.
LavanchyD.Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.J Viral Hepat2004; 11: 97–107.
2.
KonopnickiD., MocroftA., de WitS.Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.AIDS2005; 19: 593–601.
3.
BodsworthN., CooperD., DonovanB.The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state.J Infect Dis1991; 163: 1138–1140.
4.
KrogsgaardK., BindslevN., ChristensenE.The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).J Hepatol1994; 21: 646–655.
5.
MarcellinP., LauG.K.K., BoninoF.Peginterferon alpha-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.N Engl J Med2004; 351: 1206–1217.
6.
LauG.K., PiratvisuthT., LuoK.X.Peginterferon Alpha-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.N Engl J Med2005; 352: 2682–2695.
7.
BenhamouY., BochetM., ThibaultV.Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.Hepatology1999; 30: 1302–1306.
8.
MarcellinP., ChangT-T, LimS.G.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N Engl J Med2003; 348: 808–816.
9.
HadziyannisS.J., TassopoulosN.C., HeathcoteE.J.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.N Engl J Med2003; 348: 800–807.
10.
SchooleyR.T., RuaneP.A., MyersR.A.Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.AIDS2002; 16: 1257–1263.
11.
LadaO., BenhamouY., CahourA.In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.Antivir Ther2004; 9: 353–363.
12.
BenhamouY., TubianaR., ThibaultV.Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.N Engl J Med2003; 348: 177–178.
13.
LacombeK., GozlanJ., BoelleP.Y.Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.AIDS2005; 19: 907–915.
14.
DandoT., PloskerG.Adefovir dipivoxil: a review of its use in chronic hepatitis B.Drugs2003; 63: 2215–2234.
15.
van BömmelF., WμnscheT., MaussS.Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.Hepatology2004; 40: 1421–1425.
16.
PetersM.G., AndersenJ., LynchP.Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.Hepatology2006; 44: 1110–1116.
17.
LacombeK., MassariV., GirardP.M.Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV.AIDS2006; 20: 419–427.
18.
TranN., BerneR., ChannR.European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes.J Clin Microbiol2006; 44: 2792–2800.
19.
BenhamouY.Treatment algorithm for chronic hepatitis B in HIV-infected patients.J Hepatol2006; 44Suppl 1: S90–S94.
20.
BedossaP., PoynardT.An algorithm for the grading of activity in chronic hepatitis C.Hepatology1996; 24: 289–293.
21.
BrookM., McDonaldJ., KarayiannisP.Randomized controlled trial of interferon alpha 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response.Gut1989; 30: 1116–1122.
22.
LeemansW.F., JanssenH.L., NiestersH.G.Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.J Viral Hepat2008; 15: 108–114.
23.
YuenM., FongD., WongD.Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response.Hepatology2007; 46: 1695–1703.
24.
LaiC., GaneE., LiawY.Telbivudine versus lamivudine in patients with chronic hepatitis B.N Engl J Med2007; 357: 2576–2588.
25.
LaiC.L., ChienR.N., LeungN.W.A one-year trial of lamivudine for chronic hepatitis B.N Engl J Med1998; 339: 61–68.
26.
BenhamouY., ThibaultV., VigP.Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.J Hepatol2006; 44: 62–67.
27.
ChenC.H., WangJ.H., LeeC.M.Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.Antivir Ther2006; 11: 771–778.
28.
LacombeK., OllivetA., GozlanJ.A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient.AIDS2006; 20: 2229–2231.
29.
de Vries-SluijsT.E., van der EijkA.A., HansenB.E.Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV– HBV co-infected patients.J Clin Virol2006; 36: 60–63.
30.
BenhamouY., FleuryH., TrimouletP.Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.Hepatology2006; 43: 548–555.
31.
SheldonJ., CaminoN., RodesB.Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.Antivir Ther2005; 10: 727–734.
32.
DelaneyWt, RayA., YangH.Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.Antimicrob Agents Chemother2006; 50: 2471–2477.
33.
RockstrohJ.K., BhaganiS., BenhamouY.European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.HIV Med2008; 9: 82–88.
34.
DelaugerreC., MarcelinA.G., ThibaultV.Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.Antimicrob Agents Chemother2002; 46: 1586–1588.
35.
SheldonJ.A., CorralA., RodesB.Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.AIDS2005; 19: 2036–2038.
36.
LiawY F.. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy.Antivir Ther2006; 11: 669–679.
37.
VilleneuveJ.P., CondreayL.D., WillemsB.Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.Hepatology2000; 31: 207–210.
38.
HadziyannisS., TassopoulosN., HeathcoteE.J.Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.Gastroenterology2006; 131: 1743–1751.
39.
MalletV.O., Dhalluin-VenierV., VerkarreV.Reversibility of cirrhosis in HIV/HBV coinfection.Antivir Ther2007; 12: 279–283.
40.
MarcellinP., ButiM., KrastevZ.A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174-0102.Hepatology2007; 46: Abstract LB2.
41.
HeathcoteE.J., GaneE., de ManR.A.A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-0102.Hepatology2007; 46: Abstract LB6.
42.
PerrilloR P.. Acute fares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.Gastroenterology2001; 120: 1009–1022.
43.
PolS., LebrayP., Vallet-PichardA.HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms.Clin Infect Dis2004; 38Suppl 2: S65–S72.
44.
RehermannB.Immune responses in hepatitis B virus infection.Semin Liver Dis2003; 23: 21–38.
45.
MarraF., BrunoR., GalastriS.gp120 induces directional migration of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis.Hepatology2007; 46: Abstract A125.
46.
ChanH.L., HeathcoteE.J., MarcellinP.Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.Ann Intern Med2007; 147: 745–754.
